![](https://webarchive.library.unt.edu/eot2008/20090509072524im_/http://www.cancer.gov/images/spacer.gif) |
|
Bone Cancer Trial Results
1. Experimental Drug for Osteosarcoma Improves Overall Survival (Posted: 03/04/2008) - Patients with osteosarcoma who received the experimental drug mifamurtide (L-MTP-PE) along with chemotherapy fared better than patients who received chemotherapy alone, according to the Feb. 1, 2008, Journal of Clinical Oncology.
![](https://webarchive.library.unt.edu/eot2008/20090509072524im_/http://www.cancer.gov/images/spacer.gif)
2. Improved Survival for Those With Ewing Sarcoma (Posted: 02/27/2003, Reviewed: 02/01/2005) - Addition of the drugs ifosfamide and etoposide to standard chemotherapy for Ewing sarcoma significantly improved five-year survival in patients whose disease had not spread to other organs, according to the February 20, 2003, issue of the New England Journal of Medicine.
![](https://webarchive.library.unt.edu/eot2008/20090509072524im_/http://www.cancer.gov/images/spacer.gif)
3. For Transplant Patients, Oral Antinausea Drug May Be Cheaper, Just as Effective (Posted: 03/14/2002, Reviewed: 03/23/2005) - For patients receiving high-dose chemotherapy or radiation to prepare them for a bone marrow transplant (BMT), intravenous antiemetics have seemed better than oral agents at controlling nausea and vomiting. Now the results of a November 2001 study challenge this assumption.
|
|
![](https://webarchive.library.unt.edu/eot2008/20090509072524im_/http://www.cancer.gov/images/spacer.gif) |